This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The over-all goals of this application are: 1) To assess the safety and efficacy of peginterferon alfa-2a (PEG-2a) in combination with ribavirin (RV) and PEG-2a alone for the treatment of chronic hepatitis C virus (CHC) infection in children. 2) TO determine whether PEG-2a in combination with RV or PEG-2a alone will result in a higher sustained virologic response rate in children with CHC. 3) To examine the effects of PEG-2a (wuith or without concomitant RV) treatment on body mass index, body composition, and linear growth in children infected with hepatitis C. 4) To characterize short- and long-term outcomes, including health-related QOL, gognitive and developmental and psychological functioning and behavior in children treated with PEG-2a (withor without concomitant RV).
Showing the most recent 10 out of 463 publications